Literature DB >> 16987905

Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro.

R Obata1, A Iriyama, Y Inoue, H Takahashi, Y Tamaki, Y Yanagi.   

Abstract

OBJECTIVE: To investigate the expression of proangiogenic and antiangiogenic factors, vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) in retinal pigment epithelial (RPE) cells after photodynamic therapy (PDT), especially focusing on their change in the presence of triamcinolone acetonide.
METHODS: Firstly, the cellular uptake of verteporfin was quantified after confluent ARPE-19 (human retinal pigment epithelial) cells were exposed to 5 microg/ml verteporfin combined with or without 1 microg/ml triamcinolone acetonide for 1 h. Secondly, ARPE-19 cells exposed to various doses of verteporfin were irradiated with 120 mJ/cm(2) light. After incubation with or without 1 microg/ml triamcinolone acetonide for 2 days, cell viability and expressions of VEGF and PEDF were assessed.
RESULTS: Cellular uptake of verteporfin was not significantly changed by the presence of 1 microg/ml triamcinolone acetonide. In addition, 0.01-0.1 microg/ml of verteporfin showed a dose-dependent toxicity on the ARPE-19 cells 2 days after the light exposure. The presence of verteporfin at a concentration of 0.01 microg/ml did not affect the cell viability but significantly increased VEGF (p<0.001) and reduced PEDF (p = 0.03) expression. Administration of triamcinolone acetonide significantly suppressed both this increase in VEGF (p<0.001) and decrease in PEDF (p = 0.001).
CONCLUSIONS: VEGF was increased and PEDF reduced in cultured RPE cells shortly after PDT even at a sublethal dose. Triamcinolone acetonide suppressed this proangiogenic response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16987905      PMCID: PMC1857564          DOI: 10.1136/bjo.2006.098004

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  41 in total

1.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

2.  Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF.

Authors:  K Ohno-Matsui; I Morita; J Tombran-Tink; D Mrazek; M Onodera; T Uetama; M Hayano; S I Murota; M Mochizuki
Journal:  J Cell Physiol       Date:  2001-12       Impact factor: 6.384

3.  Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor.

Authors:  V Stellmach; S E Crawford; W Zhou; N Bouck
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-23       Impact factor: 11.205

4.  Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy.

Authors:  U E Schnurrbusch; K Welt; L C Horn; P Wiedemann; S Wolf
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

5.  Effect of photodynamic therapy on the function of the outer blood-retinal barrier in an in vitro model.

Authors:  Stefan Mennel; Silvia Peter; Carsten H Meyer; Gabriele Thumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-19       Impact factor: 3.117

6.  Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization.

Authors:  K Mori; E Duh; P Gehlbach; A Ando; K Takahashi; J Pearlman; K Mori; H S Yang; D J Zack; D Ettyreddy; D E Brough; L L Wei; P A Campochiaro
Journal:  J Cell Physiol       Date:  2001-08       Impact factor: 6.384

7.  Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.

Authors: 
Journal:  Retina       Date:  2002-04       Impact factor: 4.256

8.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

9.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

Authors:  N M Bressler
Journal:  Arch Ophthalmol       Date:  2001-02

10.  Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

Authors:  Magdalena G Krzystolik; Mehran A Afshari; Anthony P Adamis; Jacques Gaudreault; Evangelos S Gragoudas; Norman A Michaud; Wenjun Li; Edward Connolly; Charles A O'Neill; Joan W Miller
Journal:  Arch Ophthalmol       Date:  2002-03
View more
  6 in total

1.  Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab.

Authors:  Kohei Ishikawa; Hiroaki Nishihara; Shinsuke Ozawa; Chang-Hua Piao; Yasuki Ito; Mineo Kondo; Hiroko Terasaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-31       Impact factor: 3.117

2.  Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy.

Authors:  Isao Nakata; Akitaka Tsujikawa; Kenji Yamashiro; Atsushi Otani; Sotaro Ooto; Yumiko Akagi-Kurashige; Naoko Ueda-Arakawa; Daisuke Iwama; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-25       Impact factor: 3.117

3.  Triamcinolone acetonide prevents oxidative stress-induced tight junction disruption of retinal pigment epithelial cells.

Authors:  Yoko Miura; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-02-03       Impact factor: 3.117

4.  Effect of posterior juxtascleral triamcinolone acetonide on the efficacy and choriocapillaris hypoperfusion of photodynamic therapy.

Authors:  Aya Iriyama; Ryo Obata; Yuji Inoue; Hidenori Takahashi; Yasuhiro Tamaki; Yasuo Yanagi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-09-06       Impact factor: 3.117

5.  Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone.

Authors:  P P Yip; C F Woo; H H Y Tang; C K Ho
Journal:  Br J Ophthalmol       Date:  2009-03-08       Impact factor: 4.638

6.  Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.

Authors:  Hamid Ahmadieh; Ramin Taei; Masoud Soheilian; Mohammad Riazi-Esfahani; Reza Karkhaneh; Alireza Lashay; Mohsen Azarmina; Mohammad Hossein Dehghan; Siamak Moradian
Journal:  BMC Ophthalmol       Date:  2007-06-07       Impact factor: 2.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.